Previous 10 | Next 10 |
SAN DIEGO and ANN ARBOR, Mich., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract research, development, and manufacturing organization specializing in...
SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology , an international journal f...
Daré Bioscience ( DARE -0.4% ) received a notice of award of a grant from the Eunice Kennedy Shriver NICHD, a division of the National Institutes of Health. More news on: Daré Bioscience, Inc., Healthcare stocks news, Read more ...
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Develo...
Daré Bioscience, Inc. (DARE) Q2 2020 Results Earnings Conference Call August 12, 2020, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participa...
Dare Bioscience (NASDAQ: DARE ) : Q2 GAAP EPS of -$0.27 misses by $0.10 . More news on: Daré Bioscience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2020 and provided a company update. “During the second quarter, we cont...
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group’s ...
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 12, 2020, to review i...
Daré Bioscience ( DARE ) has initiated Phase 1 trial of DARE-HRT1, as a potential hormone replacement therapy (HRT) for vasomotor symptoms (hot-flashes) in post-menopausal women. More news on: Daré Bioscience, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...